Q4 2024 Earnings Call Transcript March 17, 2025 Operator: Good morning, ladies and gentlemen, and welcome to the NRx ...

The clinical-stage biopharmaceutical firm is pushing its NMDA platform while building a national network of psychiatric ...

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, ...

NRx Pharmaceuticals (NASDAQ:NRXP – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a research note issued to investors on Thursday,Benzinga reports. They ...

NRx Pharmaceuticals has an Earnings ESP of -0.20% and a Zacks Rank #3 at present. You can see the complete list of today’s Zacks #1 Rank stocks here. Factors Shaping NRXP's Upcoming Results In ...

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on earnings, a ...

Both have anticipated PDUFA dates prior to December 31, 2025 The Company has accepted non-binding potential terms from a commercial pharmaceutical company to license and distribute NRX-100 ...

NRx Pharmaceuticals NRXP is expected to report its fourth-quarter 2024 results soon. The Zacks Consensus Estimate for NRXP’s loss per share is pinned at 20 cents. In the absence of a marketed ...

NRx Pharmaceuticals (NASDAQ:NRXP – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at HC ...

Good morning, ladies and gentlemen, and welcome to the NRx Pharmaceuticals 4Q and Full Year 2024 Earnings Call. At this time, all lines are in a listen only mode. Following the presentation ...

NRX-100 is poised to address the >$3 billion Suicidal Depression market in the US. The Company has accepted non-binding potential terms from a commercial pharmaceutical company to license and ...